NASDAQ:APM Aptorum Group (APM) Stock Price, News & Analysis $0.97 -0.03 (-3.00%) Closing price 03:53 PM EasternExtended Trading$0.97 +0.00 (+0.41%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aptorum Group Stock (NASDAQ:APM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aptorum Group alerts:Sign Up Key Stats Today's Range$0.94▼$1.0050-Day Range$0.71▼$1.1652-Week Range$0.46▼$7.49Volume22,832 shsAverage Volume612,720 shsMarket Capitalization$5.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Read More… Aptorum Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreAPM MarketRank™: Aptorum Group scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aptorum Group. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAptorum Group has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aptorum Group's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.52% of the float of Aptorum Group has been sold short.Short Interest Ratio / Days to CoverAptorum Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptorum Group has recently decreased by 46.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAptorum Group does not currently pay a dividend.Dividend GrowthAptorum Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.52% of the float of Aptorum Group has been sold short.Short Interest Ratio / Days to CoverAptorum Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptorum Group has recently decreased by 46.24%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.03 News SentimentAptorum Group has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aptorum Group this week, compared to 0 articles on an average week.Search Interest1 people have searched for APM on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Aptorum Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptorum Group insiders have not sold or bought any company stock.Percentage Held by Insiders63.99% of the stock of Aptorum Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.80% of the stock of Aptorum Group is held by institutions.Read more about Aptorum Group's insider trading history. Receive APM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptorum Group and its competitors with MarketBeat's FREE daily newsletter. Email Address APM Stock News HeadlinesAptorum Group Ltd: Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 22 at 1:15 AM | finanznachrichten.deAptorum Group faces Nasdaq delisting over share priceApril 18, 2025 | uk.investing.comTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 25, 2025 | Crypto 101 Media (Ad)Aptorum Group faces Nasdaq minimum bid price warningApril 18, 2025 | uk.investing.comAptorum Group receives Nasdaq non-compliance notificationApril 18, 2025 | markets.businessinsider.comAptorum Group Faces Nasdaq Bid Price Compliance ChallengeApril 16, 2025 | tipranks.comAptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price ...April 16, 2025 | gurufocus.comAptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price ...April 16, 2025 | gurufocus.comSee More Headlines APM Stock Analysis - Frequently Asked Questions How have APM shares performed this year? Aptorum Group's stock was trading at $2.80 at the beginning of 2025. Since then, APM stock has decreased by 65.2% and is now trading at $0.9740. View the best growth stocks for 2025 here. When did Aptorum Group's stock split? Aptorum Group's stock reverse split on the morning of Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Aptorum Group? Shares of APM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aptorum Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptorum Group investors own include Pfizer (PFE), Meta Platforms (META), Adobe (ADBE), Cisco Systems (CSCO), Walt Disney (DIS), Gilead Sciences (GILD) and Amgen (AMGN). Company Calendar Today4/25/2025Next Earnings (Estimated)4/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APM CIK1734005 Webwww.aptorumgroup.com Phone442080929299FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.24 Current Ratio1.16 Quick RatioN/A Sales & Book Value Annual Sales$430,000.00 Price / Sales11.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book0.33Miscellaneous Outstanding Shares5,182,000Free Float1,866,000Market Cap$5.03 million OptionableNot Optionable Beta-0.24 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:APM) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.